News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
Targeting KIT by frameshifting mRNA transcripts as a therapeutic strategy for aggressive mast cell neoplasm
The sensors have been tested for their different level of strains like micro and large scale motion monitoring and have potential applications in biomedical devices, skin electronics, and minimally invasive surgery
High-resolution image-based ART workflow software uses artificial intelligence to provide objective embryo grading, to assist embryologists during embryo selection
The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial
The healthcare vertical is US-focused, has 35-plus clients and 24,000 employees across 34 locations in five countries
Deal signed with AOP Orphan for US commercial rights
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
The transaction is expected to close in the Q4FY22
Subscribe To Our Newsletter & Stay Updated
